[Scintigraphy of the bone marrow for the evaluation of injuries caused by antiblastic agents].
For various reasons the well-known myelopoietic damage caused by cancer chemotherapy is not easy to quantify by means of usual diagnostic procedures. The bone marrow scan with a Tc 99m-nanocolloid rapidly cleared by the phagocytic action of the RES, which has a topographic extension similar to red marrow, has been used for many years to evaluate the inflammatory and neoplastic diseases, both localized and diffuse. Such examination was thus performed in patients undergoing cytostatic therapy, either to follow-up metastatic lesions or to evaluate a tissue damage due to different drugs. The BMS is easily performed and has no side-effects. It consists of a dynamic and a static part. Moreover, it helped pointing out important diagnostic data, such as the reduction of the sacroiliac uptake index below the normal values (3.7) in 33 out of 57 cases, and an abnormal distribution of nanocolloid in the skeleton (Munz's classification, 1983) in 37 out of 69 cases, higher in more myelotoxic cytostatics, which could be detected even after a few months.
Ciambellotti
E
E
Servizio di Medicina Nucleare, Rodolfo Caraccio-Ospedale Civile-Biella VC.
Cartia
G L
GL
Coda
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000000981:diagnostic imaging* / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013667:Technetium; D013668:Technetium Tc 99m Aggregated Albumin
D000970:Antineoplastic Agents; D013668:Technetium Tc 99m Aggregated Albumin; D013667:Technetium
Scintigrafia del midollo osseo per la valutazione del danno da farmaci antiblastici.